Verition Fund Management
CCCC icon

Verition Fund Management’s C4 Therapeutics CCCC Stock Holding History

Verition Fund Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-69,628
Closed -$251K – 3359
2024
Q4 		$251K Buy
+69,628
New +$346K ﹤0.01% 2863
2023
Q4 		– Sell
-31,388
Closed -$58.4K – 2367
2023
Q3 		$58.4K Sell
31,388
-43,612
-58% -$133K ﹤0.01% 2172
2023
Q2 		$206K Buy
75,000
+64,812
+636% +$208K ﹤0.01% 1836
2023
Q1 		$32K Buy
+10,188
New +$60K ﹤0.01% 1986

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Verition Fund Management's CCCC Position: Q1 2025 in Review

Verition Fund Management sold out of C4 Therapeutics (CCCC) in Q1 2025, closing a stake of 69,628 shares — an estimated $251K sold.

Verition Fund Management first reported a position in CCCC in Q1 2023 and held it in 4 quarters. The position peaked at $251K in Q4 2024. 114 funds tracked by Wall St. Rank hold CCCC as of Q1 2025.

  • Verition Fund Management reported no remaining C4 Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Verition Fund Management sold 69,628 C4 Therapeutics shares in Q1 2025, an estimated $251K.
  • Verition Fund Management first reported a position in C4 Therapeutics in Q1 2023 and held it in 4 quarters.
  • Verition Fund Management's C4 Therapeutics position peaked at $251K in Q4 2024.
  • 114 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2025.

Based on Verition Fund Management's 13F filing for Q1 2025, filed 15 May 2025.